IMM Share PerformanceMore
|52 week high||102.10 09/10/17|
|52 week low||31.44 09/11/16|
|52 week change||52.88 (140.07%)|
|4 week volume||12,757,897 20/09/17|
Latest News« previous» nextMore
16/10/2017 - 15:29 RNS
RNS Number: 7306T Immupharma PLC 16 October 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma Plc 213800VZKGHXC7VUS895 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK iss...
04/10/2017 - 07:35 StockMarketWire
ImmuPharma has announced the completion of the sharing agreement entered into with Lanstead Capital in February 20...
04/10/2017 - 07:00 RNS
RNS Number: 6150S Immupharma PLC 04 October 2017 4 OCTOBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Completion of Lanstead Sharing Agreement ImmuPharma plc (LSE: IMM), the specialist drug discovery and development company , wishes to announce the completion of the Sharing Agreement entered into with Lanstead Capital L....
27/09/2017 - 08:06 StockMarketWire
ImmuPharma's operating losses narrowed slightly in the six months to end of June falling to 3,186,951 from 3,239,547. Reven...
27/09/2017 - 07:00 RNS
RNS Number: 8856R Immupharma PLC 27 September 2017 FOR IMMEDIATE RELEASE 27 SEPTEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2017 ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and develo...
26/09/2017 - 07:00 RNS
RNS Number: 7616R Immupharma PLC 26 September 2017 RNS: FOR IMMEDIATE RELEASE 26 September 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") ImmuPharma initiates preparation of Lupuzor's regulatory submissions ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to confirm a furthe...
21/09/2017 - 07:00 RNS
RNS Number: 3535R Immupharma PLC 21 September 2017 21 September 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...
19/09/2017 - 09:46 StockMarketWire
ImmuPharma, the specialist drug discovery and development company, has confirmed that it would announce its results f...
|Dividend yield||0 %|
Latest discussion posts More
“That was a lucky top up over 100% gain @ #1 / :-)”▼
“Nice to Michu - interesting that you have sold some of your holding. I am keeping all mine that I have accumulated over many years at an average of 62P. This is the first time ...”▼
“maybe it's buy and hold institutional money coming in here.. I sold another 10% at 100p just now.. maybe I shouldnt be selling at all .. only time will tell .. still have a ...”▼
Codes & Symbols
|Symbols||IMM, LSE:IMM, IMM.L, IMM:LN, LON:IMM, XLON:IMM|